You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies
|
|---|---|
| Published in |
BMC Cardiovascular Disorders, May 2016
|
| DOI | 10.1186/s12872-016-0260-0 |
| Pubmed ID | |
| Authors |
Ling Li, Sheyu Li, Jiali Liu, Ke Deng, Jason W. Busse, Per Olav Vandvik, Evelyn Wong, Zahra N. Sohani, Malgorzata M. Bala, Lorena P. Rios, German Malaga, Shanil Ebrahim, Jiantong Shen, Longhao Zhang, Pujing Zhao, Qunfei Chen, Yingqiang Wang, Gordon H. Guyatt, Xin Sun |
| Abstract |
The effect of glucagon-like peptide-1(GLP-1) receptor agonists on heart failure remains uncertain. We therefore conducted a systematic review to assess the possible impact of GLP-1 agonists on heart failure or hospitalization for heart failure in patients with type 2 diabetes. We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL) and ClinicalTrials.gov to identify randomized controlled trials (RCTs) and observational studies that addressed the effect of GLP-1 receptor agonists in adults with type 2 diabetes, and explicitly reported heart failure or hospitalization for heart failure. Two paired reviewers screened reports, collected data, and assessed the risk of bias. We pooled data from RCTs and observational studies separately, and used the GRADE approach to rate the quality of evidence. We identified 25 studies that were eligible for our review; 21 RCTs (n = 18,270) and 4 observational studies (n = 111,029). Low quality evidence from 20 RCTs suggested, if anything, a lower incidence of heart failure between GLP-1 agonists versus control (17/7,441 vs. 19/4,317; odds ratio (OR) 0.62, 95 % confidence interval (CI) 0.31 to 1.22; risk difference (RD) 19 fewer, 95 % CI 34 fewer to 11 more per 1000 over 5 years). Three cohort studies comparing GLP-1 agonists to alternative agents provided very low quality evidence that GLP-1 agonists do not increase the incidence of heart failure. One RCT provided moderate quality evidence that GLP-1 agonists were not associated with hospitalization for heart failure (lixisenatide vs placebo: 122/3,034 vs. 127/3,034; adjusted hazard ratio 0.96, 95 % CI 0.75 to 1.23; RD 4 fewer, 95 % CI 25 fewer to 23 more per 1000 over 5 years) and a case-control study provided very low quality evidence also suggesting no association (GLP-1 agonists vs. other anti-hyperglycemic drugs: 1118 cases and 17,626 controls, adjusted OR 0.67, 95 % CI 0.32 to 1.42). The current evidence suggests that GLP-1 agonists do not increase the risk of heart failure or hospitalization for heart failure among patients with type 2 diabetes. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 25% |
| Unknown | 3 | 75% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 116 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | <1% |
| United States | 1 | <1% |
| Russia | 1 | <1% |
| Canada | 1 | <1% |
| Unknown | 112 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 16 | 14% |
| Researcher | 15 | 13% |
| Student > Master | 14 | 12% |
| Student > Ph. D. Student | 10 | 9% |
| Other | 6 | 5% |
| Other | 26 | 22% |
| Unknown | 29 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 48 | 41% |
| Nursing and Health Professions | 9 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 5% |
| Agricultural and Biological Sciences | 6 | 5% |
| Biochemistry, Genetics and Molecular Biology | 5 | 4% |
| Other | 8 | 7% |
| Unknown | 34 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 May 2016.
All research outputs
#14,849,861
of 22,870,727 outputs
Outputs from BMC Cardiovascular Disorders
#742
of 1,616 outputs
Outputs of similar age
#178,124
of 309,583 outputs
Outputs of similar age from BMC Cardiovascular Disorders
#13
of 38 outputs
Altmetric has tracked 22,870,727 research outputs across all sources so far. This one is in the 33rd percentile – i.e., 33% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,616 research outputs from this source. They receive a mean Attention Score of 3.9. This one is in the 48th percentile – i.e., 48% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 309,583 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 39th percentile – i.e., 39% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 38 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 52% of its contemporaries.